分享好友 资讯首页 频道列表

Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor

2025-06-03 09:2916440

Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo (p<0.0001)
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Treatment was well-tolerated, with low incidence of treatment discontinuation and dose reductions
Not intended for Canada-, UK- or US-based media

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER trial evaluating pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., in the treatment of patients with tenosynovial giant cell tumor (TGCT). Once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) compared with placebo at week 25 (54.0% vs. 3.2% for placebo (p<0.0001). The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT. These findings will be presented Sunday, June 1 in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #11500).

“The impact that TGCT has on patients goes far beyond the physical presence of the tumor. It affects their ability to work, to move freely, and to engage in everyday activities," said Prof. Niu Xiaohui, Director of the Bone and Soft Tissue Tumour Diagnosis and Research Centre at Beijing Jishuitan Hospital. “In MANEUVER, we observed the highest ORR seen to date with a systemic therapy, together with statistically significant improvements in measures of pain, stiffness, and range of motion. These improvements in outcomes that matter to patients with TGCT and the physicians who care for them show the potential of pimicotinib to allow patients to go about their daily lives with fewer negative effects of their disease.”

In MANEUVER, which enrolled patients from China, Europe and North America, the effect of pimicotinib had an early onset, with 41.3 % (26 of 63) of patients experiencing objective response to therapy after 13 weeks. By the data cutoff for primary analysis, nearly all patients in the pimicotinib group (58 of 63 patients; 92.1%) had a decrease in tumor size per BIRC based on RECIST v1.1; one patient achieved a complete response and 33 patients achieved a partial response. The median duration of response was not reached by the data cutoff. The analysis of tumor volume score (TVS, an endpoint designed specifically for TGCT) showed that nearly two-thirds of patients treated with pimicotinib experienced a reduction in tumor volume of at least 50% (61.9% vs. 3.2% for placebo, p<0.0001).

Pimicotinib also demonstrated statistically significant and clinically meaningful improvement across all additional secondary endpoints relevant to patients’ daily lives, and these improvements were seen regardless of achieving objective tumor response to pimicotinib. Pimicotinib improved active range of motion (p=0.0003) and physical function measured by PROMIS-PF scale (p=0.0074). Pimicotinib also reduced worst stiffness (p<0.0001) and worst pain (p<0.0001).

“TGCT, although rare, has a significant impact on the daily lives of the primarily working-age adults who live with the disease, due to swelling, pain, stiffness, and limited mobility caused by the growth of these tumors in and around the joints,” said Danny Bar-Zohar, appointed CEO Healthcare and current Global Head of R&D and Chief Medical Officer. “The landmark global Phase 3 MANEUVER study data will help redefine how TGCT is treated, and we plan regulatory submissions to start this year.”

Pimicotinib was well-tolerated, and the safety profile was consistent with previously reported data, with no evidence of cholestatic hepatotoxicity or hair/skin hypopigmentation. Treatment-emergent adverse events (TEAEs) leading to treatment discontinuation occurred in one patient (1.6%) treated with pimicotinib; TEAEs leading to dose reduction occurred in 7.9% (n=5) of pimicotinib-treated patients.

About MANEUVER

The pivotal Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pimicotinib in patients with TGCT who require systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy. The study is being conducted by Abbisko Therapeutics in China (n=45), Europe (n=28), and the US and Canada (n=21).

In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of pimicotinib (n=63) or placebo (n=31) for 24 weeks. The primary endpoint is objective response rate (ORR) at week 25, as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review in the intent-to-treat (ITT) population. Secondary endpoints include tumor volume score, active range of motion, stiffness by Numeric Rating Scale (NRS), pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS).

After the double-blind Part 1, eligible patients could continue to the open-label Part 2 for up to 24 weeks of dosing, results of which are expected in mid-2025. Patients who complete Part 2 may then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up.

About Pimicotinib (ABSK021)

Pimicotinib (ABSK021), which is being developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib was recently granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of patients with tenosynovial giant cell tumor (TGCT) who require systemic therapy. Pimicotinib has been granted breakthrough therapy designation (BTD) for the treatment of unresectable TGCT by China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck holds worldwide commercialization rights for pimicotinib.

Advancing the Future of Cancer Care

At Merck, we strive every day to improve the futures of people living with cancer. Building on our 350-year global heritage as pharma pioneers, we are focusing our most promising science to target cancer’s deepest vulnerabilities, pursuing differentiated molecules to strike cancer at its core. By developing new therapies that can help advance cancer care, we are determined to create a world where more cancer patients will become cancer survivors. Learn more at www.merckgroup.com.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck, generated sales of € 21.2 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

All Merck, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.Merckgroup.com/subscribe to register for your online, change your selection or discontinue this service.

 

Contacts

Media Relations
gangolf.schrimpf@emdgroup.com
Phone: +49 151 1454 9591

Investor Relations
investor.relations@merckgroup.com
Phone: +49 6151 72-3321

反对 0
举报 0
收藏 0
打赏 0
评论 0
SiPearl:完成由台湾 Cathay Venture、EIC Fund 和 France 2030 共同参与的 1.3 亿欧元 A 轮融资
欧洲史上最复杂处理器 Rhea1 完成流片,将用于欧洲首台 百亿亿次超级计算机 JUPITER 欧洲无晶圆厂半导体行业最大 A 轮融资,新增 3200 万欧元资金,以完成 A 轮并筹备 B 轮 加强与台湾半导体生态系统的联系,助力欧洲在超算和人工智能领域的自主地位 法国梅松—拉菲特--(美国商业资讯)-- SiPearl 是一家专注于为超级计算与人工智能打造欧洲高性能、节能处理器的公司,现已完成总额达 1.3 亿欧元的 A 轮融资,第三轮募资 3200 万欧元。 Si...

0评论2025-07-111166

1GLOBAL与Odido借助SimWallet重新定义按需5G连接
阿姆斯特丹--(美国商业资讯)--技术驱动型全球移动通信供应商1GLOBAL已与荷兰领先移动运营商Odido达成合作,为独立移动应用程序SimWallet的推出提供技术支持,该应用专注于eSIM连接服务。SimWallet于今年4月进入荷兰市场。它能让用户近乎即时地接入Odido在荷兰的5G网络,且无论是否为Odido现有客户均可使用。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20250709838431/z...

0评论2025-07-111601

Andersen Consulting深化网络安全能力
旧金山--(美国商业资讯)-- Andersen Consulting与总部位于约旦的信息安全咨询公司IT Security Consulting & Training展开合作,持续提升自身咨询能力。 IT Security Consulting & Training由管理合伙人Muntaser Bdair于2011年创立,专注于为政府、金融及工业领域的客户提供服务,在治理、风险与合规(GRC)、技术测试、托管安全服务、隐私保护、抗风险能力及更广泛的网络安全举措方面具备专...

0评论2025-07-111102

Venture Global与SEFE宣布扩大液化天然气合作关系
弗吉尼亚州阿灵顿--(美国商业资讯)-- Venture Global, Inc. (NYSE: VG)与Securing Energy for Europe GmbH (SEFE)今日宣布敲定一项协议,根据该协议,SEFE的子公司SEFE Energy GmbH将在20年内从Venture Global的第三个项目——CP2 LNG额外采购每年75万吨的液化天然气(LNG)。今天的公告对双方于2023年签署的现有购销协议进行了修订,将SEFE从CP2 LNG采购的L...

0评论2025-07-111503

Rimini Street to Report Second Quarter 2025 Financial Results on July 31, 2025
LAS VEGAS--(BUSINESS WIRE)--Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMwa...

0评论2025-07-111254

LambdaTest 推出 Smart Branching 和 Baseline Management 功能,革新视觉测试工作流程
SmartUI 现已与实际开发流程保持一致,消除基线管理的混乱,使跨团队视觉质量保证更加轻松高效 旧金山--(美国商业资讯)-- LambdaTest 是一个由生成式 AI 驱动的质量工程平台,近日宣布推出 SmartUI 的 Smart Branching 和 Baseline Management 功能,标志着视觉测试领域的重大突破。此次更新解决了由过时基线策略导致的长期瓶颈问题,并引入一种智能、精简的方式,使开发团队能够在复杂的 Git 工作流中高效管理视觉测试。 现代开发团队通常采...

0评论2025-07-111138

Laserfiche荣获2025年Gartner Peer Insights文件管理领域“客户之选”殊荣
Laserfiche连续六年荣膺“客户之选”殊荣 美国加利福尼亚州长滩--(美国商业资讯)-- Laserfiche —— 领先的智能内容管理与业务流程自动化SaaS提供商 —— 荣登《2025年Gartner Peer Insights客户之声:文件管理》报告“客户之选”象限。该荣誉基于客户评价授予。在该报告中,位于右上象限的“客户之选”厂商,需在“用户兴趣与采纳度”以及&...

0评论2025-07-111625

全新NY3資料中心協助Options躋身美國交易基礎設施擴張核心
紐約、倫敦、芝加哥和香港--(美國商業資訊)--資本市場基礎設施領域的領導廠商Options Technology (Options)今日宣布,其業務新近已擴大至NY3資料中心——這是Equinix位於紐澤西州錫考克斯的全新頂尖International Business Exchange™ (IBX)資料中心,毗鄰關鍵交易樞紐NY4和NY5。 本新聞稿包含多媒體資訊。完整新聞稿請見此: https://www.businesswire.com/new...

0评论2025-07-111702

百奥赛图与百济神州达成抗体分子许可协议,加速创新药物开发
中国北京和美国麻省剑桥--(美国商业资讯)--百奥赛图(HKEX:02315),一家创新技术驱动新药研发的国际性生物技术公司,今日宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20250709152706/zh-CN/ 百济神州此前已获得百奥赛图RenMice®全人抗体平台的授权使用许可,本次双方在已建立的良好合作基础上进一步将合作拓展至抗...

0评论2025-07-111448

LambdaTest支持在iOS真实设备上进行Playwright测试,提升移动测试准确性
新功能助力QA团队在真实iPhone和iPad上实现Playwright脚本自动化,带来无可比拟的移动测试精度 旧金山--(美国商业资讯)--由生成式AI驱动的质量工程平台LambdaTest宣布支持在真实iOS设备上进行Playwright测试,使移动Web团队能够使用Safari在真实的iPhone和iPad上运行自动化测试。这一更新有助于QA和工程团队以远高于模拟器或仿真器的精度验证用户体验。 在虚拟环境中测试移动Web应用,往往会导致与真实场景的行为差异,例如遗漏触摸交互、浏览器渲...

0评论2025-07-111382